#EMA

EU Regulator Backs NewAmsterdam's Cholesterol Drug Obicetrapib, Opening Path to Market

The EMA's CHMP has recommended approval of obicetrapib (Ubeslo) and its fixed-dose combo with ezetimibe (Evlarco) for pr...